Publicaciones en colaboración con investigadores/as de Hospital Universitario de Basurto (96)

2024

  1. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

  2. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

  3. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  4. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64

  3. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  4. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 137-144

  5. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

    Molecular cancer, Vol. 22, Núm. 1, pp. 119

  6. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  7. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  8. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies

    Clinical Chemistry and Laboratory Medicine, Vol. 61, Núm. 12, pp. 2115-2130

  9. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: Methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies

    Clinical Chemistry and Laboratory Medicine, Vol. 61, Núm. 12, pp. 2131-2142

  10. Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”

    Journal of the American Academy of Dermatology

  11. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

  12. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

  13. Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series

    Gastroenterologia y Hepatologia

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  3. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients

    Transplantation, Vol. 106, Núm. 7, pp. 1430-1439